US Pharma MarketingContineum, J&J
J&J and Contineum Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals:…
Contineum Therapeutics and Johnson & Johnson’s oral M1 receptor inhibitor has missed its second mid-stage study in a year, this time in major depressive disorder.
The drug, called PIPE-307 or JNJ-5120, failed to show statistically ...
Source: Endpoints News